Form 4 for SGMT Sagimet Biosciences Inc.
Accepted 2023-07-20 00:00:00 ET · period of report 2023-07-18 · accession 0001104659-23-082735 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2023-07-20 | 2023-07-18 | SGMT | Wu Jinzi Jason | Dir | C - Cnv Deriv | — | +1.65M | 1.65M | New | — |
| DMI | 2023-07-20 | 2023-07-18 | SGMT | Wu Jinzi Jason | Dir | C - Cnv Deriv | $0.00 | -131.51M | 0 | -100% | $0 |
| D | 2023-07-20 | 2023-07-18 | SGMT | Wu Jinzi Jason | Dir | A - Grant | $0.00 | +23.2K | 23.2K | New | $0 |
| D | 2023-07-20 | 2023-07-18 | SGMT | Wu Jinzi Jason | Dir | D - Sale to Iss | $0.00 | -23.2K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Series A Common Stock | 2023-07-18 | C | A | 1,654,701 | — | 1,654,701 | I By AP11 Limited | — | — | (F1) Upon closing of the Issuer's initial public offering, each share of Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date. (F2) Shares held directly by AP11 Limited, a subsidiary of Ascletis Pharma Inc. ("Ascletis"). The Reporting Person is founder, chairman and chief executive officer of Ascletis. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. |
| 2 | Derivative | Series F Preferred Stock | 2023-07-18 | C | D | 23,041,474 | $0.00 | 0 | I By AP11 Limited | — · — to — | 289,908 Series A Common Stock | (F2) Shares held directly by AP11 Limited, a subsidiary of Ascletis Pharma Inc. ("Ascletis"). The Reporting Person is founder, chairman and chief executive officer of Ascletis. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. (F1) Upon closing of the Issuer's initial public offering, each share of Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date. |
| 3 | Derivative | Stock Option (Right to Buy) | 2023-07-18 | A | A | 23,216 | $0.00 | 23,216 | D | $6.36 · — to 2029-04-27 | 23,216 Series A Common Stock | (F4) The shares underlying this option are fully vested and exercisable as of the date hereof. |
| 4 | Derivative | Stock Option (Right to Buy) | 2023-07-18 | D | D | 23,216 | $0.00 | 0 | D | $6.36 · — to 2029-04-27 | 23,216 Common Stock | (F4) The shares underlying this option are fully vested and exercisable as of the date hereof. |
| 5 | Derivative | Series E Preferred Stock | 2023-07-18 | C | D | 108,471,634 | $0.00 | 0 | I By AP11 Limited | — · — to — | 1,364,793 Series A Common Stock | (F2) Shares held directly by AP11 Limited, a subsidiary of Ascletis Pharma Inc. ("Ascletis"). The Reporting Person is founder, chairman and chief executive officer of Ascletis. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose. (F1) Upon closing of the Issuer's initial public offering, each share of Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date. |